BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 36205627)

  • 21. Renin-angiotensin system modulation and outcomes in patients hospitalized for interstitial SARS-CoV2 pneumonia: a cohort study.
    Landolfo M; Maino A; Di Salvo E; Fiorini G; Peterlana D; Borghi C
    Intern Emerg Med; 2022 Aug; 17(5):1335-1341. PubMed ID: 35064437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Associations Between the Use of Renin-Angiotensin System Inhibitors and the Risks of Severe COVID-19 and Mortality in COVID-19 Patients With Hypertension: A Meta-Analysis of Observational Studies.
    Dai XC; An ZY; Wang ZY; Wang ZZ; Wang YR
    Front Cardiovasc Med; 2021; 8():609857. PubMed ID: 33981731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and the Risk of SARS-CoV-2 Infection or Hospitalization With COVID-19 Disease: A Systematic Review and Meta-Analysis.
    Tleyjeh IM; Bin Abdulhak AA; Tlayjeh H; Al-Mallah MH; Sohail MR; Hassett LC; Siller-Matula JM; Kashour T
    Am J Ther; 2020 Dec; 29(1):e74-e84. PubMed ID: 33395057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China.
    Li J; Wang X; Chen J; Zhang H; Deng A
    JAMA Cardiol; 2020 Jul; 5(7):825-830. PubMed ID: 32324209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renin-angiotensin system antagonists are associated with lower mortality in hypertensive patients with COVID-19.
    Megaly M; Glogoza M
    Scott Med J; 2020 Nov; 65(4):123-126. PubMed ID: 32807019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perioperative angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adults.
    Zou Z; Yuan HB; Yang B; Xu F; Chen XY; Liu GJ; Shi XY
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD009210. PubMed ID: 26816003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin enzyme inhibitors and angiotensin receptor blockers as protective factors in COVID-19 mortality: a retrospective cohort study.
    Yahyavi A; Hemmati N; Derakhshan P; Banivaheb B; Karimi Behnagh A; Tofighi R; TehraniYazdi A; Kabir A
    Intern Emerg Med; 2021 Jun; 16(4):883-893. PubMed ID: 33085063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients.
    Farid Fahmy S; El Derany MO; Khorshid H; Saleh A; El-Demerdash E
    BMC Pharmacol Toxicol; 2023 Apr; 24(1):24. PubMed ID: 37060024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in hypertensive patients with myocardial infarction or heart failure: a systematic review and meta-analysis.
    Ohtsubo T; Shibata R; Kai H; Okamoto R; Kumagai E; Kawano H; Fujiwara A; Kitazono T; Murohara T; Arima H
    Hypertens Res; 2019 May; 42(5):641-649. PubMed ID: 30948834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Associastion of In-hospital Use of Statins, Aspirin, and Renin-Angiotensin-Aldosterone Inhibitors with Mortality and ICU Admission Due to COVID-19.
    Vahedian-Azimi A; Rahimibashar F; Najafi A; Kidde J; Shahriary A; Shojaei S; Pourhoseingholi MA; Jamialahmadi T; Sahebkar A
    Adv Exp Med Biol; 2021; 1327():205-214. PubMed ID: 34279841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials.
    Tai C; Gan T; Zou L; Sun Y; Zhang Y; Chen W; Li J; Zhang J; Xu Y; Lu H; Xu D
    BMC Cardiovasc Disord; 2017 Oct; 17(1):257. PubMed ID: 28982370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of angiotensin converting enzyme inhibitors/angiotensin receptor blockers on the risk of all-cause mortality and other clinical outcomes in patients with confirmed COVID-19: A systemic review and meta-analysis.
    Jia N; Zhang G; Sun X; Wang Y; Zhao S; Chi W; Dong S; Xia J; Zeng P; Liu D
    J Clin Hypertens (Greenwich); 2021 Sep; 23(9):1651-1663. PubMed ID: 34320275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Pivotal Role of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertension Management and Cardiovascular and Renal Protection: A Critical Appraisal and Comparison of International Guidelines.
    Alcocer LA; Bryce A; De Padua Brasil D; Lara J; Cortes JM; Quesada D; Rodriguez P
    Am J Cardiovasc Drugs; 2023 Nov; 23(6):663-682. PubMed ID: 37668854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health outcomes and economic consequences of using angiotensin-converting enzyme inhibitors in comparison with angiotensin receptor blockers in the treatment of arterial hypertension in the contemporary Polish setting.
    Wrona W; Budka K; Filipiak KJ; Niewada M; Wojtyniak B; Zdrojewski T
    Kardiol Pol; 2016; 74(9):1016-24. PubMed ID: 27112942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renin-Angiotensin Aldosterone System Inhibitors and COVID-19: A Systematic Review and Meta-Analysis Revealing Critical Bias Across a Body of Observational Research.
    Loader J; Taylor FC; Lampa E; Sundström J
    J Am Heart Assoc; 2022 Jun; 11(11):e025289. PubMed ID: 35624081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative efficacy of individual renin-angiotensin system inhibitors on major renal outcomes in diabetic kidney disease: a network meta-analysis.
    Cai J; Huang X; Zheng Z; Lin Q; Peng M; Shen D
    Nephrol Dial Transplant; 2018 Nov; 33(11):1968-1976. PubMed ID: 29579289
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients.
    Baral R; White M; Vassiliou VS
    Curr Atheroscler Rep; 2020 Aug; 22(10):61. PubMed ID: 32830286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy and colorectal cancer: a systematic review and meta-analysis.
    Dai YN; Wang JH; Zhu JZ; Lin JQ; Yu CH; Li YM
    Cancer Causes Control; 2015 Sep; 26(9):1245-55. PubMed ID: 26081426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).
    Mehta N; Kalra A; Nowacki AS; Anjewierden S; Han Z; Bhat P; Carmona-Rubio AE; Jacob M; Procop GW; Harrington S; Milinovich A; Svensson LG; Jehi L; Young JB; Chung MK
    JAMA Cardiol; 2020 Sep; 5(9):1020-1026. PubMed ID: 32936273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients.
    Zhang L; Zeng X; Fu P; Wu HM
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009120. PubMed ID: 24953826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.